Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$462.13 USD
+5.26 (1.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $461.89 -0.24 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRTX 462.13 +5.26(1.15%)
Will VRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Stay Ahead of the Game With Vertex (VRTX) Q2 Earnings: Wall Street's Insights on Key Metrics
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Other News for VRTX
Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more
KBRA Assigns Preliminary Ratings to VRTX 2025-HQ | VRTX Stock News
Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200
ClearBridge Growth Portfolios Q2 2025 Commentary